https://www.selleckchem.com/pr....oducts/CP-690550.htm
Patients receiving BRMs had 2.4 times more DCM compared to pulmonary CM (PCM). AI does not increase the risk of any specific CM clinical presentation, and BRM treatment of most AI patients does not lead to severe CM. However, BRMs significantly increase the risk of DCM, and prospective studies are needed to identify the immunogenetic subset that permits BRM-associated DCM. AI does not increase the risk of any specific CM clinical presentation, and BRM treatment of most AI patients does not lead to severe CM. However, BRMs significantl
Like
Comment
Share
